administering to the patient the ALK Inhibitor and an immunogenic polypeptide comprising amino acids cysteine 6 to cysteine 42 of an Epidermal Growth Factor (EGF) at an amount effective to generate an immune response against the EGF, wherein the cysteine residues are numbered relative to amino acids 1 to 52 of SEQ ID NO: 2, or an immunogenic polypeptide comprising SEQ ID NO: 2;

wherein the ALK Inhibitor is selected from the group consisting of Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib, and pharmaceutically acceptable salts thereof;

wherein the ALK Inhibitor is administered in a therapeutically effective daily dose in a range of about 10 mg to about 250 mg and the immunogenic polypeptide is administered according to a therapeutically effective repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly to generate polyclonal antibodies targeting EGF.